1. India’s GST cuts viewed as boosting auto and consumption activity 2. Rising renewable energy capacity seen as central to India’s resilience story 3. Export growth targeted via pharmaceuticals, auto ancillaries and speciality chemicals 4. Aurobindo Pharma and Mahindra & Mahindra cited as key portfolio holdings Mugunthan Siva from India Avenue Investment Management sets out a constructive but more cautious outlook on India, highlighting both resilience and near-term risks in the economy and equity market. Siva points to the World Bank’s upgraded Indian growth forecast of 6.6% for FY26–27 and notes that GST rationalisation is already, in his view, driving stronger consumption in autos, cars and motorbikes. He argues that policy is deliberately shifting towards domestic demand to offset export and tariff headwinds. Energy remains a key risk from the Middle East crisis, yet Siva stresses India’s growing resilience, with fossil fuels’ share of energy use falling and roughly half of incremental capacity now coming from renewables such as solar, hydro and wind. Renewables are seen as a major investment theme over the next five years, though Siva stresses the need for economic viability and sensible valuations. He also highlights India’s push to build export “sectoral champions” in auto ancillaries, speciality chemicals and pharmaceuticals. Within his own strategy, Siva uses a barbell between local consumption and export earners, citing positions in Aurobindo Pharma and Mahindra & Mahindra as preferred exposures. He expects Indian earnings growth into FY27 to moderate to around 5–10% amid the current crisis and softer private capex. Click Here To Watch The Video
